Key facts
- Crescita Therapeutics Inc. has closed its plan of arrangement with ClinActiv Holdings Inc.
- ClinActiv's subsidiary acquired all issued and outstanding common shares of Crescita.
- Shareholders will receive $0.80 per share in cash consideration.
- Crescita Therapeutics Inc. will cease to be a publicly traded company.
LAVAL, Québec -- Crescita Therapeutics Inc. announced the closing of its previously announced plan of arrangement with ClinActiv Holdings Inc. and its wholly-owned subsidiary, the Purchaser. The Purchaser acquired all issued and outstanding common shares of Crescita in exchange for cash consideration of $0.80 per share. Crescita Therapeutics Inc. trades on the TSX under the symbol CTX and over-the-counter in the US under the symbol CRRTF.